Perrigo (PRGO) Stock Price, News & Analysis

Company Overview

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Key Stats

• Today's Range: $24.60 to $25.09
• 50-Day Range: $24.09 to $29.50
• 52-Week Range: $23.14 to $33.46
• Volume: 976,890 shs
• Average Volume: 1.52 million shs
• Market Capitalization: $3.39 billion
• P/E Ratio: N/A
• Dividend Yield: 4.66%
• Price Target: $33.00
• Consensus Rating: Hold

Perrigo Stock Analysis - MarketRank™

Perrigo scored higher than 97% of companies evaluated by MarketBeat, and ranked 9th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Perrigo has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Perrigo has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 19.53%

Earnings Growth

Earnings for Perrigo are expected to grow by 19.53% in the coming year, from $2.56 to $3.06 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Perrigo is -21.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Perrigo is -21.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Perrigo has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.94% of the float of Perrigo has been sold short.

Short Interest Ratio / Days to Cover

Perrigo has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Perrigo has recently increased by 5.01%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Leadership

Perrigo is a leading dividend payer. It pays a dividend yield of 4.68%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Perrigo has been increasing its dividend for 23 years.

Dividend Sustainability

Based on earnings estimates, Perrigo will have a dividend payout ratio of 37.91% next year. This indicates that Perrigo will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 3.5 / 5
• Environmental Score: -1.93

Percentage of Shares Shorted

2.94% of the float of Perrigo has been sold short.

Short Interest Ratio / Days to Cover

Perrigo has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Perrigo has recently increased by 5.01%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.18

News Sentiment

Perrigo has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for Perrigo this week, compared to 7 articles on an average week.

Search Interest

Only 8 people have searched for PRGO on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.

MarketBeat Follows

6 people have added Perrigo to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Perrigo insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $214,032.00 in company stock.

Percentage Held by Insiders

Only 0.70% of the stock of Perrigo is held by insiders.

Percentage Held by Institutions

95.91% of the stock of Perrigo is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PRGO Stock Analysis - Frequently Asked Questions

How have PRGO shares performed this year?

Perrigo's stock was trading at $25.71 at the beginning of 2025. Since then, PRGO shares have decreased by 3.3% and is now trading at $24.87.
View the best growth stocks for 2025 here.

How were Perrigo's earnings last quarter?

Perrigo Company plc (NYSE:PRGO) posted its earnings results on Thursday, February, 27th. The company reported $0.93 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.92 by $0.01. The company had revenue of $1.14 billion for the quarter, compared to analysts' expectations of $1.20 billion. Perrigo had a negative net margin of 3.64% and a positive trailing twelve-month return on equity of 7.38%.

Does Perrigo have any subsidiaries?

Perrigo subsidiaries include HRA Pharma, Ranir, Laboratoire de la Mer SAS, Geiss Destin & Dunn, ScarAway, Omega Pharma, Elan Corporation, and others.

Who are Perrigo's major shareholders?

Top institutional shareholders of Perrigo include Copeland Capital Management LLC (1.80%), Perpetual Ltd (1.40%), Allspring Global Investments Holdings LLC (0.84%) and Sound Income Strategies LLC (0.37%). Insiders that own company stock include Svend Andersen, Ronald Craig Janish, Geoffrey M Parker, James E Dillard III, Robert Willis, Patrick Lockwood-Taylor, Alison Ives, Grainne Quinn, Eduardo Guarita Bezerra, Katherine C Doyle, Jeffrey B Kindler, Thomas Farrington and Murray S Kessler.
View institutional ownership trends.

How do I buy shares of Perrigo?

Shares of PRGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Perrigo own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Perrigo investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 2/27/2025
• Record date for 3/25 Dividend: 3/07/2025
• Ex-Dividend for 3/25 Dividend: 3/07/2025
• Dividend Payable: 3/25/2025
• Today: 4/24/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:PRGO
• CIK: 1585364
• Web: www.perrigo.com
• Phone: (531) 709-4000
• Fax: 269-673-9128
• Employees: 8,900
• Year Founded: 1887

Price Target and Rating

• Average Stock Price Target: $33.00
• High Stock Price Target: $42.00
• Low Stock Price Target: $27.00
• Potential Upside/Downside: +32.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 9.71
• P/E Growth: N/A
• Net Income: $-12,700,000.00
• Net Margins: -3.64%
• Pretax Margin: -4.67%
• Return on Equity: 7.38%
• Return on Assets: 3.18%

Debt

• Debt-to-Equity Ratio: 0.94
• Current Ratio: 2.56
• Quick Ratio: 1.77

Sales & Book Value

• Annual Sales: $4.37 billion
• Price / Sales: 0.78
• Cash Flow: $5.19 per share
• Price / Cash Flow: 4.79
• Book Value: $35.19 per share
• Price / Book: 0.71

Miscellaneous

• Outstanding Shares: 136,459,000
• Free Float: 135,473,000
• Market Cap: $3.39 billion
• Optionable: Optionable
• Beta: 0.49